KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Thermo Fisher Scientific (TMO) EBT Margin (2016 - 2025)

Thermo Fisher Scientific's EBT Margin history spans 17 years, with the latest figure at 17.63% for Q4 2025.

  • For the quarter ending Q4 2025, EBT Margin rose 59.0% year-over-year to 17.63%, compared with a TTM value of 16.4% through Dec 2025, down 1.0%, and an annual FY2025 reading of 16.4%, down 1.0% over the prior year.
  • EBT Margin for Q4 2025 was 17.63% at Thermo Fisher Scientific, up from 16.42% in the prior quarter.
  • The five-year high for EBT Margin was 27.79% in Q2 2021, with the low at 12.73% in Q2 2023.
  • Average EBT Margin over 5 years is 17.49%, with a median of 16.56% recorded in 2023.
  • Biggest YoY gain for EBT Margin was 1450bps in 2021; the steepest drop was -1006bps in 2021.
  • Tracing TMO's EBT Margin over 5 years: stood at 17.4% in 2021, then dropped by -11bps to 15.52% in 2022, then grew by 3bps to 15.98% in 2023, then rose by 7bps to 17.03% in 2024, then increased by 3bps to 17.63% in 2025.
  • Per Business Quant, the three most recent readings for TMO's EBT Margin are 17.63% (Q4 2025), 16.42% (Q3 2025), and 15.74% (Q2 2025).